Dendritic cell vaccines

Methods in Molecular Biology

Volumn 1403, Issue , 2016, Pages 763-777

  Sabado, Rachel Lubong ^a   Meseck, Marcia ^a   Bhardwaj, Nina ^a  

^a NONE

Author keywords

Dendritic cell; Immune response; Immunotherapy; Tumor; Vaccine

Indexed keywords

ANTIGEN; DENDRITIC CELL VACCINE; CANCER VACCINE; CYTOKINE;

CELL DIFFERENTIATION; CELL MATURATION; HUMAN; IMMUNE RESPONSE; CELL CULTURE TECHNIQUE; CELL SEPARATION; CLINICAL TRIAL (TOPIC); CYTOLOGY; DENDRITIC CELL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY;

CANCER VACCINES; CELL CULTURE TECHNIQUES; CELL SEPARATION; CLINICAL TRIALS AS TOPIC; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY;

EID: 84963808582     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3387-7_44     Document Type: Chapter

References (64)

1. Palucka K, Banchereau J (2013) Dendriticcell- based therapeutic cancer vaccines. Immunity 39:38–48
2. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146
3. Vignali DA, Kuchroo VK (2012) IL-12 family cytokines: immunological playmakers. Nat Immunol 13:722–728
4. McKenna K, Beignon AS, Bhardwaj N (2005) Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 79:17–27
5. Drobits B, Holcmann M, Amberg N, Swiecki M et al (2012) Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 122:575–585
6. Gandhi RT, O’Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J et al (2009) A randomized therapeutic vaccine trial of canarypox-HIVpulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 27:6088–6094
7. Palucka AK, Ueno H, Connolly J, Kerneis- Norvell F et al (2006) Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29:545–557
8. Redman BG, Chang AE, Whitfield J, Esper P et al (2008) Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 31:591–598
9. Sabado RL, Miller E, Spadaccia M, Vengco I, Hasan F, Bhardwaj N (2013) Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. J Vis Exp (78)
10. Miller E, Spadaccia M, Sabado R, Chertova E et al (2015) Autologous aldrithiol-2- inactivated HIV-1 combined with polyinosinicpolycytidylic acid-poly-l-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. Vaccine 33: 388–395
11. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S et al (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458
12. Marroquin CE, Westwood JA, Lapointe R, Mixon A et al (2002) Mobilization of dendritic cell precursors in patients with cancer by fl t3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother 25:278–288
13. Kantoff PW, Higano CS, Shore ND, Berger ER et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
14. Small EJ, Schellhammer PF, Higano CS, Redfern CH et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094
15. Sikora AG, Hailemichael Y, Overwijk WW (2012) Conference scene: immune effector mechanisms in tumor immunity. Immunotherapy 4:141–143
16. Adams S, O’Neill D, Bhardwaj N (2004) Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines. J Clin Oncol 22:3834–3835
17. Lee AW, Truong T, Bickham K, Fonteneau JF et al (2002) A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20(Suppl 4):A8–A22
18. Jongmans W, Tiemessen DM, van Vlodrop IJ, Mulders PF, Oosterwijk E (2005) Th1- polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother 28:480–487
19. Krause P, Singer E, Darley PI, Klebensberger J et al (2007) Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leukoc Biol 82:1106–1114
20. Morelli AE, Thomson AW (2003) Dendritic cells under the spell of prostaglandins. Trends Immunol 24:108–111
21. Kwissa M, Nakaya HI, Oluoch H, Pulendran B (2012) Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119:2044–2055
22. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R (2001) Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2:947–950
23. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6:769–776
24. Boullart AC, Aarntzen EH, Verdijk P, Jacobs JF et al (2008) Maturation of monocytederived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 57:1589–1597
25. Bogunovic D, Manches O, Godefroy E, Yewdall A et al (2011) TLR4 engagement during TLR3-induced proinfl ammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 71:5467–5476
26. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al (2004) alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64:5934–5937
27. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P (2008) Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol 84:319–325
28. Whitehurst AW (2014) Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol 54:251–272
29. Andrews MC, Woods K, Cebon J, Behren A (2014) Evolving role of tumor antigens for future melanoma therapies. Future Oncol 10: 1457–1468
30. Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74
31. Carreno BM, Magrini V, Becker-Hapak M et al (2015) A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigenspecific T cells. Science 348:803–808
32. O’Neill D, Bhardwaj N (2005) Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. Methods Mol Med 109:97–112
33. Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:351–360
34. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R (2008) Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 38:1033–1042
35. Barrou B, Benoit G, Ouldkaci M, Cussenot O et al (2004) Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53:453–460
36. Salcedo M, Bercovici N, Taylor R, Vereecken P et al (2006) Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 55:819–829
37. Mahdian R, Kokhaei P, Najar HM, Derkow K, Choudhury A, Mellstedt H (2006) Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHCrestricted antigen-specific antitumor T cells. Med Oncol 23:273–282
38. Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A (2001) Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 61:6445–6450
39. Thumann P, Moc I, Humrich J, Berger TG, Schultz ES, Schuler G, Jenne L (2003) Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods 277:1–16
40. Wheeler CJ, Black KL (2009) DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 18:509–519
41. Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C et al (2005) Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105:2465–2472
42. Jenne L, Schuler G, Steinkasserer A (2001) Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 22:102–107
43. Brockstedt DG, Dubensky TW (2008) Promises and challenges for the development of Listeria monocytogenes-based immunotherapies. Expert Rev Vaccines 7:1069–1084
44. Bellone S, El-Sahwi K, Cocco E, Casagrande F et al (2009) Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J Virol 83:6779–6789
45. Carrasco J, Van Pel A, Neyns B, Lethe B, Brasseur F et al (2008) Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 180:3585–3593
46. Butterfield LH, Comin-Anduix B, Vujanovic L et al (2008) Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 31:294–309
47. Veron P, Allo V, Riviere C, Bernard J, Douar AM, Masurier C (2007) Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J Virol 81:5385–5394
48. Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK (2002) Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235:540–549
49. Muller MR, Tsakou G, Grunebach F, Schmidt SM, Brossart P (2004) Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 103: 1763–1769
50. Nencioni A, Muller MR, Grunebach F, Garuti A, Mingari MC, Patrone F, Ballestrero A, Brossart P (2003) Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther 10:209–214
51. Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P (2003) Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101:977–982
52. Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199:251–263
53. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J (2001) Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 61:3388–3393
54. Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A (2000) Human dendritic cells transfected with either RNA or DNA encoding infl uenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 7:2028–2035
55. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J (2000) Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165:5713–5719
56. Heiser A, Coleman D, Dannull J, Yancey D et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109:409–417
57. Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C et al (2010) Immunologic activity and safety of autologous HIV RNAelectroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 134:140–147
58. Teijeira A, Russo E, Halin C (2014) Taking the lymphatic route: dendritic cell migration to draining lymph nodes. Semin Immunopathol 36:261–274
59. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC et al (2009) Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15:2531–2540
60. Fujiwara S, Wada H, Miyata H, Kawada J, Kawabata R et al (2012) Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J Immunother 35:513–521
61. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ et al (2011) Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17:5725–5735
62. Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N (2010) CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One 5(6):e11144
63. Mitchell DA, Batich KA, Gunn MD, Huang MN et al (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366–369
64. Garcia F, Climent N, Guardo AC, Gil C, Leon A, Autran B, Lifson JD, Martinez-Picado J, Dalmau J, Clotet B, Gatell JM, Plana M, Gallart T (2013) A dendritic cell-based vaccine elicits t cell responses associated with control of HIV-1 replication. Sci Transl Med 5(166):166-1162